Authors: Jeff Leya, Kyle Hines, HEPSI KALAPALA, CHRISTINA QUILLIAN, Salvator Gutierrez, Sonia Thomas, marianne tully
Published: 2024-11-11
DOI: 10.1161/circ.150.suppl_1.4140167
Source: Full article
ASCVD is the most prevalent form of cardiovascular disease and the main cause of morbidity and mortality for Veterans in the VA healthcare system. Management of cholesterol is one of the most effective approaches for reducing CV disease, however, over two-thirds of Veterans with ASCVD are not optimally managed. Veterans with ASCVD are at high risk for recurrent CV events and can benefit greatly from more effective management of their low-density lipoprotein (LDL-C) cholesterol. The reasons for the current undertreatment of dyslipidemia in Veterans with ASCVD are multifaceted, including factors such as low disease awareness among the patients, patient’s preference, statin intolerance, and poor adherence to medications.